Market cap is the total market value to buy the whole company. It is equal to the share price times the number of Shares Outstanding (EOP). Fortrea Holdings's share price for the quarter that ended in Mar. 2024 was $40.14. Fortrea Holdings's Shares Outstanding (EOP) for the quarter that ended in Mar. 2024 was 89 Mil. Therefore, Fortrea Holdings's market cap for the quarter that ended in Mar. 2024 was $3,587 Mil.
Fortrea Holdings's quarterly market cap
increased
from Sep. 2023 ($2,539 Mil) to Dec. 2023 ($3,099 Mil) and
increased
from Dec. 2023 ($3,099 Mil) to Mar. 2024 ($3,587 Mil).
Fortrea Holdings's annual market cap
stayed the same
from Dec. 2021 ($0 Mil) to Dec. 2022 ($0 Mil) but then
increased
from Dec. 2022 ($0 Mil) to Dec. 2023 ($3,099 Mil).
Enterprise Value is the theoretical takeover price. It is more comprehensive than market capitalization (market cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash and cash equivalents. Fortrea Holdings's Enterprise Value for Today is $3,880 Mil.
Fortrea Holdings Market Cap Historical Data
The historical data trend for Fortrea Holdings's Market Cap can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Fortrea Holdings's Market Cap
For the Biotechnology subindustry, Fortrea Holdings's Market Cap, along with its competitors' market caps and Market Cap data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Fortrea Holdings's Market Cap Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Fortrea Holdings's Market Cap distribution charts can be found below:
* The bar in red indicates where Fortrea Holdings's Market Cap falls into.
Fortrea Holdings Market Cap Calculation
Market cap is the short version of market capitalization. It is the total market value to buy the whole company. It is equal to the share price times the number of shares outstanding.
Fortrea Holdings's Market Cap for the fiscal year that ended in Dec. 2023 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Fortrea Holdings (NAS:FTRE) Market Cap Explanation
Market cap is not the real price you pay for a company. If you buy the company and become its owner, you become the owner of the cash the company has, and you also assume the companys debt. The real price you pay is the Enterprise Value.
Warren Buffett uses the ratio of total market cap of all public traded companies over GDP to measure if the market is expensive. As of April 2012, the US total market cap is about $14.7 trillion, while the US GDP is about $15 trillion. The market was modestly overvalued.
Fortrea Holdings Market Cap Related Terms
Thank you for viewing the detailed overview of Fortrea Holdings's Market Cap provided by GuruFocus.com. Please click on the following links to see related term pages.
Fortrea Holdings (Fortrea Holdings) Business Description
Fortrea Holdings is a late-stage contract research organization, or CRO, that provides comprehensive Phase I through IV clinical trial management, clinical pharmacology, and patient access solutions. The company works with emerging and large biopharma, medical device, and diagnostic companies to run their clinical trials as a functional-service provider, full-service provider, and offers hybrid trials. In 2023, Fortrea was formed as an independent, publicly traded company after LabCorp spun off its clinical development business, which it acquired via its purchase of Covance in 2015 for $6.1 billion. Fortrea has 19,000 staff members across 90 countries.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
FTRE has been successfully added to your 